Erschienen in:
15.02.2018 | Observational Research
Canakinumab treatment in children with familial Mediterranean fever: report from a single center
verfasst von:
Fatma Yazılıtaş, Özlem Aydoğ, Sare Gülfem Özlü, Evrim Kargın Çakıcı, Tülin Güngör, Fehime Kara Eroğlu, Gökçe Gür, Mehmet Bülbül
Erschienen in:
Rheumatology International
|
Ausgabe 5/2018
Einloggen, um Zugang zu erhalten
Abstract
Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5–10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.